Search results for "Muscarinic"

showing 10 items of 263 documents

Role of non-neuronal and neuronal acetylcholine in the airways

2001

It is well known that acetylcholine represents a dominant neurotransmitter within mammalian airways and that airway functions, like smooth muscle activity and secretion, are under a continuous cholinergic tone. However, the teleology of this basal cholinergic tone, assumed to originate from neuronal activity, appears difficult to understand, whereas neuronal cholinergic reflex activity can be regarded as a rational regulatory pathway to protect the airways from injury [1-3]. Based on recent experimental observations, both phenomena may reflect two different biological roles of acetylcholine, acting first as a universal cytomolecule (non-neuronal) and second as a classical neurotransmitter (…

BiologyCholine acetyltransferasechemistry.chemical_compoundchemistryMuscarinic acetylcholine receptorReflexmedicineCholinergicPremovement neuronal activityRegulatory PathwayNeurotransmitterNeuroscienceAcetylcholinemedicine.drug
researchProduct

Acetylcholine receptors (muscarinic) in GtoPdb v.2021.2

2021

Muscarinic acetylcholine receptors (mAChRs) (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [50]) are activated by the endogenous agonist acetylcholine. All five (M1-M5) mAChRs are ubiquitously expressed in the human body and are therefore attractive targets for many disorders. Functionally, M1, M3, and M5 mAChRs preferentially couple to Gq/11 proteins, whilst M2 and M4 mAChRs predominantly couple to Gi/o proteins. Both agonists and antagonists of mAChRs are clinically approved drugs, including pilocarpine for the treatment of elevated intra-ocular pressure and glaucoma, and atropine for the treatment of bradycardia and poisoning by muscarinic age…

BradycardiaAtropineChemistryPilocarpineMuscarinic acetylcholine receptormedicinemedicine.symptomPharmacologyMuscarinic AgentsAcetylcholineEndogenous agonistmedicine.drugAcetylcholine receptorIUPHAR/BPS Guide to Pharmacology CITE
researchProduct

Plasma concentration following oral and intramuscular atropine in children and their clinical effects.

1997

In a paediatric population, we compared i.m. v oral atropine premedication to a control group without atropine and determined atropine plasma concentrations (APC). Forty-five children were randomly assigned to one of three groups. Group I received atropine, 20 micrograms.kg-1 i.m., 15 min prior to induction. Group II received atropine, 30 micrograms.kg-1 orally, group III received no atropine. APC (expressed as percent of muscarine-2 receptor subtype occupancy), heart rate, rectal temperature, and salivation were determined before atropine, and 15, 25, 45, 60, 90, 120 (no APC), and 150 min following atropine. Only 10-20% of the M2-cholinoceptors were occupied after oral atropine with a peak…

BradycardiaAtropineMalemedicine.medical_specialtyGroup iiAdministration OralMuscarinic AntagonistsInjections IntramuscularReceptor subtypeBody TemperatureHeart RateInternal medicineHeart rateMedicineHumansChildReceptor Muscarinic M2business.industryReceptors MuscarinicAtropineAnesthesiology and Pain MedicineEndocrinologyAnesthesiaChild PreschoolPediatrics Perinatology and Child HealthPlasma concentrationPremedicationFemalemedicine.symptombusinessSalivationPreanesthetic MedicationPaediatric populationmedicine.drugPaediatric anaesthesia
researchProduct

Acetylcholine receptors (muscarinic) in GtoPdb v.2021.3

2021

Muscarinic acetylcholine receptors (mAChRs) (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [50]) are activated by the endogenous agonist acetylcholine. All five (M1-M5) mAChRs are ubiquitously expressed in the human body and are therefore attractive targets for many disorders. Functionally, M1, M3, and M5 mAChRs preferentially couple to Gq/11 proteins, whilst M2 and M4 mAChRs predominantly couple to Gi/o proteins. Both agonists and antagonists of mAChRs are clinically approved drugs, including pilocarpine for the treatment of elevated intra-ocular pressure and glaucoma, and atropine for the treatment of bradycardia and poisoning by muscarinic age…

BradycardiaAtropinePilocarpineChemistryMuscarinic acetylcholine receptormedicinePharmacologymedicine.symptomMuscarinic AgentsEndogenous agonistAcetylcholinemedicine.drugAcetylcholine receptorIUPHAR/BPS Guide to Pharmacology CITE
researchProduct

Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers

2015

Introduction: The efficacy and safety of a new once-daily (QD) fixed-dose combination (FDC) with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, was established for the treatment of COPD in the TONADO studies (NCT01431274; NCT01431287). This analysis evaluates the efficacy of the FDC in a subpopulation of patients receiving β-blockers (BBs) in these studies. Methods: Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O FDC (2.5/5 μg; 5/5 μg; Respimat ® inhaler) QD compared to the monocomponents. Key primary end point data for the combined analysis of the replicate trial…

COPDmedicine.medical_specialtyRespimatbusiness.industryInhalerOlodaterolFixed-dose combinationMuscarinic antagonistmedicine.diseasechemistry.chemical_compoundchemistryInternal medicinemedicinePhysical therapyClinical endpointIn patientbusinessmedicine.drug5.1 Airway Pharmacology and Treatment
researchProduct

Ability of short-time Fourier transform method to detect transient changes in vagal effects on hearts: a pharmacological blocking study.

2006

Conventional spectral analyses of heart rate variability (HRV) have been limited to stationary signals and have not allowed the obtainment of information during transient autonomic cardiac responses. In the present study, we evaluated the ability of the short-time Fourier transform (STFT) method to detect transient changes in vagal effects on the heart. We derived high-frequency power (HFP, 0.20–0.40 Hz) as a function of time during active orthostatic task (AOT) from the sitting to standing posture before and after selective vagal (atropine sulfate 0.04 mg/kg) and sympathetic (metoprolol 0.20 mg/kg) blockades. The HFP minimum point during the first 30 s after standing up was calculated and…

Cardiac responseAdultAtropineMalemedicine.medical_specialtySympathetic Nervous SystemPhysiologyAdrenergic beta-AntagonistsPostureBlood PressureMuscarinic AntagonistsDizzinessOrthostatic vital signsPhysiology (medical)Internal medicinemedicineHeart rate variabilityHumansFourier AnalysisChemistryBlocking (radio)Short-time Fourier transformHeartVagus NerveAutonomic AgentsTime–frequency analysisSurgeryAutonomic nervous systemCardiologyTransient (oscillation)Cardiology and Cardiovascular MedicineMetoprololAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Loss of input from the mossy cells blocks maturation of newly generated granule cells.

2007

The objective of this work is to check whether the input from the mossy cells to the inner molecular layer is necessary for the integration and maturation of the newly generated granule cells of the dentate gyrus (DG) in mice, and if after status epilepticus the sprouting of the mossy fibers can substitute for this projection. Newly generated cells were labeled by administration of 5-bromo-deoxyuridine either before or after pilocarpine administration. The neuronal loss in the hippocampus after administration of pilocarpine combined with scopolamine and diazepam seemed restricted to the hilar mossy cells. The maturation of the granule cells was studied using immunohistochemistry for calreti…

Cell typeCell SurvivalCognitive NeuroscienceScopolamineConvulsantsNerve Tissue ProteinsMuscarinic Antagonistschemistry.chemical_compoundMiceS100 Calcium Binding Protein GStatus EpilepticusmedicineAnimalsCell ProliferationDiazepamEpilepsyNeuronal PlasticitybiologyChemistryDentate gyrusStem CellsGranule (cell biology)PilocarpineNuclear ProteinsCell DifferentiationImmunohistochemistryDNA-Binding Proteinsnervous systemBromodeoxyuridinePilocarpineCalbindin 2Dentate GyrusMossy Fibers HippocampalNerve Degenerationbiology.proteinAnticonvulsantsFemaleNeuNCalretininNeuroscienceBromodeoxyuridineBiomarkersSproutingmedicine.drugHippocampus
researchProduct

Expression of muscarinic receptors on the murine embryonic stem cell line CGR8

2013

Cellular and Molecular NeuroscienceEndocrine and Autonomic SystemsMuscarinic acetylcholine receptorEmbryonic Stem Cell LineNeurology (clinical)BiologyCell biologyAutonomic Neuroscience
researchProduct

Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction.

1995

The alkaloids (-)physostigmine (Phy), galanthamine (Gal) and codeine (Cod), and several derivatives and homologous compounds, can act as noncompetitive agonists (NCA) of nicotinic acetylcholine receptors (nAChR) from Torpedo electrocytes, frog and mammalian muscle cells, clonal rat pheochromocytoma cells, cultured hippocampal neurons and several ectopic expression systems, by interacting with a binding site on the alpha-subunits of these nAChRs that is insensitive to the natural transmitter, acetylcholine (ACh), and ACh-competitive agonists and antagonists. Several endogenous ligands, including opioid-type compounds, can also act via this site, albeit at higher concentrations than is typica…

Central Nervous SystemPharmacologyReceptors NicotinicLigandsBiochemistrylaw.inventionEvolution MolecularlawMuscarinic acetylcholine receptormedicineAnimalsHumansNicotinic AgonistsBinding siteReceptorMolecular BiologyAcetylcholine receptorBinding SitesMolecular StructureChemistryCell BiologyAcetylcholineCell biologyNicotinic agonistnervous systemSignal transductionAcetylcholineTorpedomedicine.drugSignal TransductionJournal of receptor and signal transduction research
researchProduct

Therapeutic Modulation of Urinary Bladder Function: Multiple Targets at Multiple Levels

2015

Storage dysfunction of the urinary bladder, specifically overactive bladder syndrome, is a condition that occurs frequently in the general population. Historically, pathophysiological and treatment concepts related to overactive bladder have focused on smooth muscle cells. Although these are the central effector, numerous anatomic structures are involved in their regulation, including the urothelium, afferent and efferent nerves, and the central nervous system. Each of these structures involves receptors for—and the urothelium itself also releases—many mediators. Moreover, hypoperfusion, hypertrophy, and fibrosis can affect bladder function. Established treatments such as muscarinic antago…

Central Nervous Systemmedicine.medical_specialtyUrinary BladderPopulationCentral nervous systemMuscarinic Antagonistsurologic and male genital diseasesToxicologyBioinformaticsMuscle hypertrophyNeurons EfferentFibrosisInternal medicinemedicineAnimalsHumansNeurons AfferentUrotheliumeducationPharmacologyeducation.field_of_studyUrinary bladderbusiness.industryUrinary Bladder DiseasesMuscle SmoothAdrenergic beta-AgonistsHyperplasiamedicine.diseasefemale genital diseases and pregnancy complicationsUrodynamicsTreatment OutcomeEndocrinologymedicine.anatomical_structureOveractive bladderAdrenergic alpha-1 Receptor AntagonistsUrological AgentsUrotheliumbusinessSignal TransductionAnnual Review of Pharmacology and Toxicology
researchProduct